Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SARS-CoV-2 plasma Clear all
Completed Phase 3 Interventional Results available

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

NCT04362176
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Immune Responses to COVID-19 Infection or Vaccination

NCT05379478
View directory record Official record
Conditions
COVID-19
Interventions
Laboratory assessment of antibody profiles
Diagnostic Test
Lead sponsor
Aditxt, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 28, 2026, 2:32 AM EDT
No Longer Available No phase listed Expanded access

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207
View directory record Official record
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional

Plasma Adsorption in Patients With Confirmed COVID-19

NCT04358003
View directory record Official record
Conditions
Respiratory Failure, ARDS
Interventions
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Device
Lead sponsor
Marker Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Convalescent Plasma vs. Standard Plasma for COVID-19

NCT04344535
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma, Standard Donor Plasma
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 28, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection

NCT04456413
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma, Best Supportive Care
Biological · Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Early Phase 1 Interventional

COVID-19 Convalescent Plasma (CCP) Transfusion

NCT04412486
View directory record Official record
Conditions
COVID-19
Interventions
COVID Convalescent Plasma
Biological
Lead sponsor
Gailen D. Marshall Jr., MD PhD
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 28, 2026, 2:32 AM EDT
No Longer Available No phase listed Expanded access

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04360486
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Anti-Sars-CoV-2 Convalescent Plasma
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
26
States / cities
Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
View directory record Official record
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Completed No phase listed Observational Results available

Evaluation of Point-of-Care (EPOC) for COVID-19

NCT05227404
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Infection
Interventions
LumiraDX, RightSign, Case Control
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients

NCT04471051
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 28, 2026, 2:32 AM EDT
Terminated Phase 3 Interventional Results available

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

NCT04348656
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma
Biological
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
16 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Household Transmission Study

NCT04445233
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 IgM-IgG Rapid Test
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year and older
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 28, 2026, 2:32 AM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Convalescent Plasma in Outpatients With COVID-19

NCT04355767
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Saline
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
53
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 28, 2026, 2:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Diagnostic Self-testing Using Virtual Point-of-care

NCT04348864
View directory record Official record
Conditions
Communicable Disease, COVID-19, Sars-CoV2, Infectious Disease, Coronavirus, Virus
Interventions
COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support, Telemedicine
Diagnostic Test · Other
Lead sponsor
Neuroganics LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 28, 2026, 2:32 AM EDT
Withdrawn Phase 1 Interventional

Intermediate IND Severe Illness COVID-19 CP

NCT04411602
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, COVID
Interventions
SARS-CoV-2 plasma
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 28, 2026, 2:32 AM EDT
Recruiting Phase 2 Interventional

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

NCT04392232
View directory record Official record
Conditions
Coronavirus, COVID-19, Convalescent Plasma
Interventions
Convalescent Plasma
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
16 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19

NCT04360278
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 28, 2026, 2:32 AM EDT